



ELSEVIER

---

## Contraception

---

Contraception 67 (2003) 493-495

### Author Index

#### Volume 67

January-June, 2003

Abetz, L., 187  
Abrams, L. S., 93  
Achiron, R., 473  
Acunzo, G., 355  
Ahued, J. R., 367  
Albrecht, G., 367  
Aleem, M., 409  
Alvarado, G., 367  
Amro, B. I., 485  
Andersen Clark, K., 287  
Andolsek-Jeras, L., 33  
Araya, R., 161  
Arreola, R. G., 367  
Ashton, J., 53  
Avecilla-Palau, À., 235  
Avonts, D., 491

Baird, D. T., 1  
Bajos, N., 39  
Bal, W., 477  
Balasinor, N., 409  
Baldaszti, E., 87  
Barambio, S., 457  
Bartholomew, N. E., 115  
Bassol, S., 367  
Bastidas, J. M., 161  
Beckman, L. J., 207  
Benson, J., 287  
Bernstein, L., 139  
Berquó, E., 385  
Bianchia, P. G., 107  
Bianchi-Demicheli, F., 107  
Bifulco, G., 277, 355  
Bigrigg, A., 259  
Bird, S. T., 207  
Blanchard, K., 343  
Blumenthal, P. D., 207  
Botti, G., 367  
Botto, E., 367  
Breitkopf, D. M., 349  
Brenning, R. K., 449  
Buicu, C., 423  
Bungay, H., 343

Campana, A., 107  
Carbonell, J. L. L., 457  
Cardenas, L., 201  
Casas, P. R. F., 367  
Celic-Gonzalez, C., 367

Cerrota, G., 277  
Çetinkaya, F., 133  
Chaki, S. P., 73  
Chami, S., 457  
Chan, C. P. B., 101  
Chen, J., 281  
Cheng, L., 1, 281  
Chies, J. A. B., 247  
Choudhuri, J., 409  
Christow, A., 319  
Chuanrong, Z., 379  
Cifuentes, R., 367  
Clark, V. A., 139  
COCON Group, 39  
Coulter, D., 53  
Creasy, G. W., 93  
Critchley, H. O. D., 467  
Croxatto, H. B., 335, 415

Dada, K., 1  
Dalve-Endres, A. M., 449  
Darney, P., 201  
Das, H. C., 73  
de Carvalho Formiga, M. C., 385  
de Cássia da Silveira e Sá, R., 327  
de la Loge, C., 187  
de Moura Reporedo, M., 327  
de Oliveira, H. C., 367  
de Pádua, K. S., 391  
de Pierro, A. N., 367  
De Simone, R., 277  
de Vargas, F., 457  
Dean, G., 201  
Denekens, J., 491  
Dhar, J. D., 403  
Di Carlo, C., 355  
Di Spiezio Sardo, A., 277, 355  
Dijak, V., 219  
Doncel, G. F., 241  
Dorflinger, L., 167  
D'Souza, S., 409  
Dudley, S., 287  
Dumont, P., 107  
Dwivedi, A. K., 403  
Dykes, A.-K., 439

Edelman, A., 9, 49  
Elgán, C., 439  
Ellertson, C., 167, 259

El-Tagy, A., 229  
Endrikat, J., 423  
Evans, M., 259

Faccin, C. S., 19  
Farley, T., 65  
Ferden, S., 259  
Fernandez, M., 367  
Fiddes, P., 313  
Fisher, A., 431  
Fletcher, J., 313  
Flores, J. G., 367  
Frezieres, R. G., 139  
Friedman, A., 431  
Fuchs, F. D., 19  
Furedi, A., 343

Gainer, E., 195  
Gallo, M. F., 15  
Gamzu, R., 267, 473  
Gaspard, U., 423  
Gemzell-Danielsson, K., 319  
Gerhardt, A., 287  
Gerlinger, C., 423  
Geroj, J., 65  
Gill-Sharma, M. K., 409  
Glasier, A. F., 1, 281, 313  
Glyn Allen, J., 93  
Goldberg, A., 201  
Gomez, J., 367  
Gómez-Mora, H., 161  
Goulard, H., 39  
Grimes, D. A., 15  
Guerrero-Carreño, F. J., 273  
Guida, M., 355  
Gupta, G., 403  
Gurucharri, C., 367

Hammarström, M., 299  
Hammond, G. L., 93  
Hardy, E., 391  
Haring, T., 271  
Harrison-Woolrych, M., 53  
Harvey, S. M., 207  
Haukkamaa, M., 223  
Hausknecht, R., 463  
Hays, M., 397  
Hebling, E. M., 391  
Heikinheimo, O., 223

Heithecker, R., 423  
 Heredia, M. G., 367  
 Ho, P. C., I, 101  
 Hopkins, K., 385  
 Hulthén Varli, I., 299

Illingworth, P. J., 467  
 Issa, A. H., 229

Jensen, J., 9, 49  
 Job-Spira, N., 39  
 Juneja, H. S., 409

Kafrissen, M., 431  
 Katz, D. F., 57  
 Keller, P. J., 79  
 Kettle, H., 492  
 Kholkute, S., 151  
 Kleszczewski, T., 477  
 Kocijancic, A., 33  
 Kostrzewska, A., 477  
 Kuhl, H., 25, 361  
 Kumar, S., 295  
 Kutschera, E., 25, 361  
 Kuyoh, M. A., 15  
 Kwiecien, M., 9

LaGuardia, K. D., 431  
 Lastreto, E., 367  
 Lavine, M. L., 57  
 Leadbetter, C., 259  
 Leal, O. F., 385  
 Lee, J. H., 25, 361  
 Lefebvre, P., 423  
 Lessing, J. B., 267  
 Lévy, D., 195  
 Li, C. F. I., 101  
 Li, X., 379  
 Lidor, A., 473  
 Lindelius, A., 299  
 Llados, C. M., 415  
 Lohr, K. N., 115  
 Lopez, C. R., 367  
 Löschke, K., 87  
 Lubianca, J. N., 19  
 Lüdicke, F., 107

Müller, A. L., 415  
 Maikhuri, J. P., 403  
 Majramkar, D. D., 409  
 Marí, J., 457  
 Marc, J., 33  
 Marions, L., 319  
 Maslovitch, S., 267  
 Mazicioğlu, M., 133  
 McNeilly, A. S., 467  
 Mellinger, U., 25, 361  
 Mercorio, F., 277  
 Merki-Feld, G. S., 79  
 Mikolajczyk, R. T., 253, 333  
 Misro, M. M., 73

Mistik, S., 133  
 Mittal, S., 295  
 Modzelewska, B., 477  
 Moore, C., 25, 361  
 Moos, M.-K., 115  
 Moreno, V., 235  
 Morrow, E., 41  
 Morrow, S., 281  
 Mulders, T. M. T., 271

Naçar, M., 133  
 Nagamani, M., 349  
 Nandedkar, T., 151  
 Ñañez, M., 367  
 Nappi, C., 277, 355  
 Narciso Leite, M., 327  
 Natarajan, J., 93  
 Nazerali, H., 397  
 Neff, M., 79  
 Nelson, A. L., 139  
 Nelson, E., 49  
 Nichols, M. D., 9, 49, 207  
 Nóbrega de Almeida, R., 327  
 Novák, A., 187

Ortiz, O. C., 367  
 Osis, M. J. D., 391  
 Otero-Flores, J. B., 273  
 Owen, D. H., 57

Pandey, K. R., 397  
 Parte, P., 409  
 Pathak, L. R., 397  
 Patrick, K., 449  
 Pauzner, D., 267  
 Peña, E. P., 367  
 Peacock, K., 139  
 Penagos, G., 367  
 Percossi, G., 367  
 Peremans, L., 491  
 Perheentupa, A., 467  
 Perpétuo, I. H. O., 385  
 Perrin, E., 107  
 Peters, J. J., 57  
 Picardo, L., 41  
 Pinter, B., 33  
 Podhradsky, L., 219  
 Pope, M., 65  
 Potter, B., 65  
 Potter, J. E., 385  
 Prezelj, J., 33  
 Prieto, G., 367

Randall, L., 287  
 Rauchfuss, M., 253  
 Reddy, P. R., 241  
 Reyes-Marquez, R., 367  
 Ricalde, R. L., 367  
 Rivera, R., 373  
 Rodríguez, J., 457  
 Rogers, K., 207

Rosen, M. P., 349  
 Rountree, W., 373  
 Rowlands, S., 421

Sánchez, C., 457  
 Sakr, E., 229  
 Salazar, G., 367  
 Salhab, A. S., 485  
 Salhan, S., 213  
 Salvador, I., 457  
 Samsioe, G., 439  
 Sanders, L., 343  
 Sarda, N., 213  
 Savaris, R., 247  
 Saxena, P., 213  
 Scheen, A., 423  
 Schiff, G., 473  
 Schramm, G., 305  
 Schulz, K. F., 15  
 Scott, A., 313  
 Setty, B. S., 403  
 Shangold, G., 431  
 Sheffer-Mimouni, G., 267  
 Shelton, J. D., 421  
 Shields, W. C., 251, 341  
 Shiyuan, L., 379  
 Shomaf, M. S., 485  
 Shulman, A., 473  
 Siiteri, P. K., 93  
 Silva, J., 367  
 Sipowicz, M., 477  
 Smith, K. B., I, 281  
 Sokal, D. C., 229, 241, 397  
 Sollet, C., 195  
 Souza, M. R., 385  
 Stanford, J. B., 253, 333  
 Steffens, D., 305  
 Stewart, F. H., 251, 341  
 Suhonen, S., 223  
 Sun, X., 319

Tanda, R., 457  
 Thapa, S., 397  
 The Norgestimate Study Group, 431  
 The Oral Contraceptive and  
 Hemostasis Study Group, 173  
 Tikka, M., 223  
 Tommaselli, G. A., 355  
 Toroitich-Ruto, C., 15  
 Torres, L. A., 367  
 Tozzini, R. I., 367  
 Trussell, J., 167, 259

Ulmann, A., 195  
 Ulmann, M., 195

Valero, F., 457  
 van der Meulen, E. A., 187  
 van der Spuy, Z. M., I  
 Van Royen, P., 491  
 Vanacore, F., 277

Vázquez-Estrada, L. A., 273  
Velazco, A., 457  
Vera, R., 161  
Verhoeven, V., 491  
Vimala, N., 295  
von Hertzen, H., 259

Wadia, P., 151  
Walsh, T. L., 139

Webb, A., 259  
Wellings, K., 1  
Westhoff, C., 41  
Wiebe, E., 219  
Wiegartz, I., 25, 361  
Wimmer-Puchinger, B., 87  
Winkler, U. H., 25, 361  
Wong, C. Y. G., 101  
Wood, B. L., 241  
Wraxall, B. G. D., 139

Xiaoping, P., 379  
Xiaoqin, C., 379

Yazlle, M. E. D. H., 367  
Young, S. L., 349

Zalel, Y., 473  
Zaneveld, L. J. D., 391





ELSEVIER

Contraception 67 (2003) 497-500

**Subject Index**  
**Volume 67**  
**January-June, 2003**

**Contraception**

Abortion experience of women, medical or surgical, 41  
Acceptability,  
  combined oral hormonal contraceptives, 281  
  levonorgestrel-releasing IUS, 87  
  manual vs electric aspiration for abortion, 201, 207  
  NuvaRing®, 187  
Acceptability of contraception, effect of amenorrhea, 1  
Access and counseling, emergency contraception, 39  
Accessory sex gland function, effect of RISUG, 73  
Adrenal parameters, effect of OCs, 361  
Advance provision service, emergency contraception, 343  
Advantage-S, rheological properties, 57  
Amenorrhea, effect of contraception, 1  
Anti-androgenic properties, ethinylestradiol +  
  chlormadinone acetate, 305  
Antifertility effect, FSH binding inhibitor (marmoset), 151  
Association of Reproductive Health Professions (ARHP)  
  editorial,  
  over-the-counter status for emergency contraception,  
    342  
  Preserving Core Values in Science Statement, 251

β3 integrin subunit expression, effect of copper, 247  
Bleeding patterns, effect of ethinyl estradiol +  
  levonorgestrel, 9  
Blood pressure, effect of OCs, 19  
Blood pressure parameters, effect of OCs, 361  
Bone mass, effect of DMPA use, 79  
Bone metabolism,  
  effect of estradiol + levonorgestrel, 33  
  influence of vitamin D receptor genotype, 33  
Bone mineral density,  
  effect of ethinyl estradiol + gestodene, 355  
  effect of smoking and OC use, 439

Cannula fracture, complication in surgical abortions, 49  
Carbohydrate metabolism, effect of OCs, 423  
Chaperones during pelvic examination, questionnaire  
  survey, 313  
Chlamydia infection screening, 491, 492  
Clinical experience, ethinyl estradiol + gestodene, 367  
College health centers, current trends for emergency  
  contraception pills, 449  
Complication, surgical abortion, 49  
Conceptrol, rheological properties, 57  
Condom failures, use of prostate-specific antigen to  
  measure semen exposure, 139  
Contraception,  
  counseling in the clinical setting, 115

effect of amenorrhea, 1  
Contraceptive effect, meloxicam (rabbit), 485  
Contraceptive gel viscosity, effect of temperature and pH,  
  57  
Contraceptive practices, before and after termination of  
  pregnancy, 107  
Contraceptive vaginal ring,  
  ethinyl estradiol + etonogestrel, 187  
  NuvaRing®, 187, 271  
Copper,  
  effect on expression of β3 integrin subunit, 247  
  effect on uterine activity, 477  
Copper IUDs, uterine factors and risk of pregnancy, 235  
Copper-bearing IUD, replacement of inert IUDs, 379  
Copper-T 380A, post-abortal insertion, 229  
Copper-vasopressin complex, effect on myometrium, 477  
Counseling, prevention of unintended pregnancy, 115  
Cupric ions, effect on spermatozoa motility, 161  
Current trends, emergency contraception pills, 449  
Depot medroxyprogesterone acetate, effect on bone mass,  
  79  
Diaphragm vs sponge for contraception, 15  
Diltiazem, effect on sperm, 241  
Discontinuation of Norplant use, effect of menstrual  
  problems, 373

Early abortion services, provider survey, 287  
Ectopic pregnancy risk, levonorgestrel emergency  
  contraception, 267  
Effectiveness,  
  emergency contraceptive pills, 259  
  ethinyl estradiol + chlormadinone acetate, 305  
  vasectomy, 397  
Efficacy, safety and cycle control, use of ethinyl  
  estradiol + norgestimate, 431  
Electric vs manual aspiration, surgical abortion, 201, 307  
Emergency contraception,  
  access and counseling, 39  
  advance provision service, 343  
  analysis of website use, 195  
  levonorgestrel, 267  
  Yuzpe regimen, 167, 259, 333, 335  
Emergency contraceptive pills,  
  current trends, 449  
  effectiveness, 259  
Ethinyl estradiol + chlormadinone acetate, efficacy and  
  tolerability, 305  
Ethinyl estradiol + desogestrel,  
  effect on carbohydrate metabolism, 423

effect on hemostatic variables, 173  
treatment of hirsutism, 349

Ethinyl estradiol + dienogest,  
effect on sex hormones and serum-binding globulins, 25  
effect on thyroid function, adrenal and blood pressure parameters, 361

Ethinyl estradiol + drospirenone, effect on carbohydrate metabolism, 423

Ethinyl estradiol + estradiol valerate + dienogest,  
effect on sex hormones and serum-binding globulins, 25  
effect on thyroid function, adrenal and blood pressure parameters, 361

Ethinyl estradiol + etonogestrel, acceptability of contraceptive vaginal ring, 187

Ethinyl estradiol + gestodene,  
clinical experience, 367  
effect on bone turnover and bone mineral density, 355  
effect on hemostatic variables, 173

Ethinyl estradiol + levonorgestrel,  
effect on bleeding patterns, 9  
effect on bone metabolism, 33  
effect on hemostatic variables, 173  
effect on sex hormones and serum-binding globulins, 25  
effect on thyroid function, adrenal and blood pressure parameters, 361  
pharmacological properties, 93  
standard vs continuous dosing regimens, 9  
treatment of hirsutism, 349

Ethinyl estradiol + norgestrel,  
effect on hemostatic variables, 173  
efficacy, safety and cycle control, 431  
pharmacological properties, 93  
triphasic regimens vs cyclophasic regimens, 431

Family planning, attitudes and behavior of married men, 133

Female condom, structural integrity after multiple reuse, 65

Female sterilization, postpartum, 385

FSH (follicle stimulating hormone)

FSH binding inhibitor, antifertility effect (marmoset), 151

Gemeprost (Cervagem®),  
effect on surgical abortion, 299  
prostaglandin analogue, 299

Gynol II, rheological properties, 57

Hemostatic variables, effect of OCs, 173

Hirsutism treatment, effect of OCs, 349

Hormone parameters, effect of OCs, 25

Hormone profile, effect of tamoxifen (monkey), 409

Hypertensive women, effect of OCs, 19

Internet website use, emergency contraception, 195

Intrauterine device (IUD),  
copper-bearing, 379  
copper-T 380A, 229  
inert, 379

ML Cu 375 sl, 273  
Multiload Cu375, 53  
TCu 380 Nul, 273  
TCu 380A, 273

Intrauterine system (IUS), levonorgestrel-releasing, 87

Intravasal RISUG, effect on semen and accessory sex gland function, 73

IUD (intrauterine device)

IUD insertion, incidence of uterine perforation, 53

IUD insertion post-abortal, safety and acceptability, 229

IUD performance, nulliparous women, 273

IUD users, uterine factors and risk of pregnancy, 235

IUS (intrauterine system)

KY Plus, rheological properties, 57

Lactation, effect of norgestrel, 467

Lamicel tent, effect on surgical abortion, 299

Learning curve, use of mifepristone + misoprostol, 223

Levonorgestrel, post-coital treatment (rat), 415

Levonorgestrel emergency contraception, risk of ectopic pregnancy, 267

Levonorgestrel-releasing IUD, treatment of myoma-related menorrhagia, 277

Levonorgestrel-releasing IUS,  
acceptability, 87  
timing of effects, 473

Lorazepam, effect during surgical abortion, 219

Male attitudes, family planning, 133

Male contraceptive, reversible inhibition of sperm under guidance (RISUG), 73

Male reproductive system, effect of *Mikania glomerata* extract (rat), 327

Manual vs electric aspiration, surgical abortion, 201, 207

Mechanism of action,  
spermicidal agents, 403  
Yuzpe regimen, 167

Medical abortion,  
mifepristone + misoprostol, 223, 463  
misoprostol, 457

Medical abortion services, provider survey, 287

Medical or surgical abortion, experience of women, 41

Meloxicam, contraceptive effect (rabbit), 485

Menorrhagia, treatment with levonorgestrel-releasing IUD, 277

Menstrual problems, effect on Norplant discontinuation, 373

Methylene blue, effect on sperm, 241

Mifepristone, effect on distribution of progesterone receptor isoform B, 319

Mifepristone + misoprostol, medical abortion, 223, 463

*Mikania glomerata* extract, effect on male reproductive system (rat), 327

Misoprostol,  
effect on surgical abortion, 101  
medical abortion, 457

Misoprostol + diclofenac sodium, effect on surgical abortion, 101

Misoprostol sublingual, effect on surgical abortion, 213, 295

ML Cu 375 sl, performance in nulliparous women, 273  
 Modern natural family planning methods, interest and use, 253  
 Motility of spermatozoa, effect of cupric ions, 161  
 Multiload Cu375, uterine perforation at insertion, 53  
 Myoma-related menorrhagia, treatment with levonorgestrel-releasing IUD, 277  
 Myometrium, effect of copper-vasopressin complex, 477  
 Natural family planning, interest and use, 253  
 Non-detergent spermicidal agents, mechanism of action, 403  
 Nonoxytol-9 + NuvaRing, interaction with ethynodiol and etonogestrel, 271  
 Norgestimate, pharmacological properties, 93  
 Norgestrel, effect on lactation, 467  
 effect on pituitary-ovarian axis, 467  
 Norplant discontinuation, effect of menstrual problems, 373  
 Nulliparous women, clinical performance of IUDs, 273  
 NuvaRing®, combined contraceptive vaginal ring, 187  
 NuvaRing + nonoxynol-9, interaction with ethynodiol and etonogestrel, 271

OC (oral contraceptive)  
 OC use and smoking, effect on bone mineral density, 439  
 Oral contraceptive (OC), ethynodiol + chlormadinone acetate, 305  
 ethynodiol + desogestrel, 173, 349, 423  
 ethynodiol + dienogest, 25, 361  
 ethynodiol + drospirenone, 423  
 ethynodiol + estradiol valerate + dienogest, 25, 361  
 ethynodiol + gestodene, 173, 355, 367  
 ethynodiol + levonorgestrel, 9, 25, 33, 93, 173, 349, 361  
 ethynodiol + norgestimate, 93, 173, 431  
 Oral contraceptives, acceptability, 281  
 effect on blood pressure, 19  
 effect on hemostatic variables, 173  
 effect on sex hormones and serum-binding globulins, 25  
 Over-the-counter status for emergency contraception, ARHP editorial, 341

Pelvic examination and chaperones, questionnaire survey, 313  
 Pharmacological properties, norgestimate, 93  
 Pituitary-ovarian axis activity, effect of norgestrel, 467  
 Post-abortion IUD insertion, safety and acceptability, 229  
 Post-fertilization events, effect of levonorgestrel (rat), 415  
 Postpartum sterilization, demand, 385  
 Pregnancy risk in IUD users, effect of uterine factors, 235  
 Pregnancy termination, contraceptive practices before and after, 107  
 Preserving Core Values in Science Statement, ARHP editorial, 251  
 Progesterone receptor isoform B, distribution following mifepristone, 319

Progesterone-only pill, norgestrel, 467  
 Prostate-specific antigen level, use to measure semen exposure, 139  
 Provider survey, early abortion services, 287  
 Quality of life, following medical or surgical abortion, 41  
 Repeat use, emergency contraception, 421  
 emergency contraceptive pills, 421  
 Reuse of female condom, structural integrity, 65  
 Rheological properties, spermicidal gels, 57  
 RISUG (reversible inhibition of sperm under guidance), 73  
 Safety, ethynodiol + chlormadinone acetate, 305  
 Semen, effect of RISUG, 73  
 Semen characteristics, effect of tamoxifen (monkey), 409  
 Semen exposure, prostatic-specific antigen level, 139  
 Serum-binding globulins, effect of OCs, 25  
 Smoking and OC use, effect on bone mineral density, 439  
 Sperm motility, effect of diltiazem, 241  
 effect of methylene blue, 241  
 Spermatozoa, effect of cupric ions on motility, 161  
 Spermicidal agents, mechanism of action, 403  
 Spermicidal gels, rheological properties, 57  
 Sponge vs diaphragm for contraception, 15  
 Structural integrity, reuse of female condoms, 65  
 Sublingual misoprostol, effect on cervical priming, 213, 295  
 Surgical abortion, effect of gemeprost for cervical priming, 299  
 effect of lamicel tent for cervical priming, 299  
 effect of lorazepam, 219  
 effect of misoprostol + diclofenac sodium for cervical priming, 101  
 effect of sublingual misoprostol for cervical priming, 213, 295  
 manual vs electric aspiration, 201, 207  
 Surgical abortion complication, plastic cannula fracture, 49  
 Surgical abortion services, provider survey, 287  
 Surgical or medical abortion, experience of women, 41

Tamoxifen, effect on semen characteristics and hormone profile (monkey), 409  
 TCu 380 Nul, performance in nulliparous women, 273  
 TCu 380A, performance in nulliparous women, 273  
 Termination of pregnancy, contraceptive practices before and after, 107  
 Thyroid function, effect of OCs, 361  
 Timing of effects, levonorgestrel-releasing IUS, 473  
 Triphasic regimens vs cyclophasic regimens, ethynodiol + norgestimate, 431

Unintended pregnancy, counseling in the clinical setting, 115  
 Uterine activity, effect of copper, 477  
 Uterine factors, effect on risk of pregnancy in IUD users, 125

Uterine perforation, complication of IUD insertion, 53

Vaginal antimicrobial contraceptives, women's preferences, 391

Vaginal ring, NuvaRing®, 187

Vasectomy, effectiveness, 397

Vitamin D receptor genotype, influence on bone metabolism, 33

Website use analysis, emergency contraception, 195

Women's preferences, vaginal antimicrobial contraceptives, 391

Yuzpe regimen, effectiveness, 259

emergency contraception, 333, 335

mechanism of action, 167

